About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline
LOG IN
LOG IN

99-100 Cornell L. Rev. Online 1 (2013-2015)

handle is hein.journals/clro2 and id is 1 raw text is: IS MORE INFORMATION ALWAYS BETTER? MANDATORY DISCLOSURE REGULATIONS IN THE PRESCRIPTION DRUG MARKET Joanna Shepherdt Pharmacy benefit managers (PBMs) save Americans billions of dollars each year by lowering the prices of prescription drugs and the costs of prescription drug coverage. However, as I explain in this Article, mandatory disclosure regulations recently enacted in several states and at the federal level under the Affordable Care Act threaten to disrupt the cost savings that PBMs currently produce for consumers. These regulations require PBMs to disclose competitively sensitive financial information to various participants in the prescription drug market. Although mandatory disclosure regulations are premised on the idea that PBM clients can only ensure that they are paying a competitive price for a PBM's services if they know the specifics of the PBM's financial arrangements with pharmaceutical manufacturers and pharmacies, there is no theoretical or empirical reason to believe mandated disclosure of this information is necessay. Not only are these regulations unnecessary to achieve competitive outcomes, they also impose significant costs on PBMs. The additional disclosure increases both direct costs and litigation costs for PBMs. More importantly, the regulations foster tacit collusion and reduce PBMs' ability to negotiate discounts with pharmacies and rebates with drug manufacturers. By disrupting competition in the prescription drug market, mandatory disclosure regulations will ultimately increase the prices that consumers pay for prescription drugs. INTRO DU CTIO N ........................................................................................ 1 I. BACKGROUND OF PHARMACY BENEFIT MANAGEMENT .................. 4 A. PBM Industry Structure ................................................... 5 B. PBM Business Model and Prescription Drug Spending ...... 6 II. MANDATORY DISCLOSURE REGULATIONS ................................... 11 A . State Regulations ................................................................. 11 B. Regulations Under the Affordable Care Act .................. 13 III. ARE MANDATORY DISCLOSURE REGULATIONS NECESSARY? ........ 14 IV. COSTS OF MANDATORY DISCLOSURE REGULATIONS ................... 17 A. Direct Costs of Disclosure ............................................... 17 B. Litigation Costs ................................................................ 18 C. Competitive Harms .......................................................... 18 C ONCLUSION ....................................................................................... 21 INTRODUCTION The prescription drug market has changed dramatically over the last few decades. Whereas consumers once paid for prescription t Associate Professor of Law, Emory University School of Law.

What Is HeinOnline?

HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.



Short-term subscription options include 24 hours, 48 hours, or 1 week to HeinOnline.

Purchase Access

Contact us for annual subscription options:

Contact Us

Already a HeinOnline Subscriber?

Log In

profiles profiles most